Effect of Octenidol® mouthrinse on cell viability and cell diameter

Objectives: The aim was to investigate the effect of the mouthrinse Octenidol® (Octinidin) on viability and diameter of fibroblasts and epithelium cells in comparison to other oral antiseptics and in relation to contact time. Methods: Besides Octenidol® the following mouthrinses were used: Chlorhexamed® 0,2% (CHX), Listerine® (essential oils), Meridol® (AmF/ZnF), Betaisodona® (PVP-Jod); control: medium only. The cells, human primary gingiva fibroblasts (HFIB-G, Provitro) and human primary nasal epithelium cells (HNEPC, Provitro), were cultivated in cell specific medium (initial cell number: 2x10E5/ml), than they were treated with the mouthrinses for 1, 5, and 15 min. Each test was carried out 12 times. Subsequently viability and cell diameter (cell counter) were determined. Statistics: Two-way analysis of variance and subsequent Dunnett tests, additional t-tests (adjusted by the method of Bonferroni). Results: In both cell lines a significant effect of the mouthrinse as well as the contact time for both parameters was observed (p<0.001). Moreover, an interaction between mouthrinse and contact time was found (p<0.001). A significant difference in both cell lines was also observed between any mouthrinse and the control (p<0.0001). Regarding the viability of the fibroblasts no difference could be found between Octenidol® and the other mouthrinses and contact times (p>0.005), whereas the viability of the epithelium cells was less influenced by Octenidol® than by Chlorhexamed®, Meridol® and Listerine® (p<0.005). The diameter of the fibroblasts and the epithelium cells was also less influenced by Octenidol® than by Chlorhexamed®, Meridol® and Listerine® (p<0.005). For both parameters and cell lines there was no difference between Octenidol® and Betaisodona® (p>0.005). Conclusions: As any of the oral antiseptics Octenidol® showed a negative effect on human fibroblasts and epithelium cells. However, regarding the viability and the diameter of the cells Octinodol® showed a less negative effect.